Skip to main content

Table 2 MBD2 genotypes, menopausal status and breast cancer risk in Caucasians

From: Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status

MBD2 genotype Cases (n = 393) Controls (n = 436) Crude OR (95% CI) ORa (95% CI)
SNP 1 (rs1259938)
All women
   G/G 210 (53.4) 226 (51.8) 1.00 1.00
   G/A 158 (40.2) 179 (41.1) 0.95 (0.71–1.27) 0.94 (0.70–1.26)
   A/A 25 (6.4) 31 (7.1) 0.86 (0.49–1.52) 0.86 (0.49–1.54)
   G/A + A/A 183 (46.6) 210 (48.2) 0.94 (0.71–1.23) 0.94 (0.71–1.24)
Premenopausal women
   G/G 59 (67.1) 69 (47.3) 1.00 1.00
   G/A 25 (28.4) 65 (44.5) 0.43 (0.24–0.77) 0.40 (0.22–0.74)
   A/A 4 (4.6) 12 (8.2) 0.39 (0.12–1.26) 0.39 (0.12–1.29)
   G/A + A/A 29 (33.0) 77 (52.7) 0.42 (0.24–0.73) 0.41 (0.23–0.72)
Postmenopausal women
   G/G 151 (49.5) 157 (54.1) 1.00 1.00
   G/A 133 (43.6) 114 (39.3) 1.24 (0.88–1.74) 1.24 (0.88–1.75)
   A/A 21 (6.9) 19 (6.6) 1.16 (0.59–2.27) 1.15 (0.58–2.29)
   G/A + A/A 154 (50.5) 134 (45.9) 1.23 (0.90–1.70) 1.24 (0.90–1.72)
SNP 2 (rs609791)
All women
   C/C 243 (63.9) 260 (61.6) 1.00 1.00
   C/G 120 (31.6) 140 (33.2) 0.92 (0.68–1.24) 0.92 (0.68–1.24)
   G/G 17 (4.5) 22 (5.2) 0.83 (0.43–1.59) 0.85 (0.44–1.64)
   C/G + G/G 237 (36.1) 162 (38.4) 0.90 (0.68–1.21) 0.91 (0.68–1.22)
Premenopausal women
   C/C 60 (70.6) 80 (56.3) 1.00 1.00
   C/G 20 (23.5) 55 (38.7) 0.48 (0.26–0.89) 0.47 (0.26–0.88)
   G/G 5 (5.9) 7 (5.0) 0.95 (0.29–3.15) 1.02 (0.30–3.49)
   C/G + G/G 25 (29.4) 62 (43.7) 0.54 (0.30–0.95) 0.54 (0.30–0.96)
Postmenopausal women
   C/C 183 (62.0) 180 (64.3) 1.00 1.00
   C/G 100 (33.9) 85 (30.4) 1.16 (0.81–1.65) 1.15 (0.80–1.64)
   G/G 12 (4.1) 15 (5.3) 0.79 (0.36–1.73) 0.80 (0.36–1.76)
   C/G + G/G 112 (38.0) 100 (35.7) 1.10 (0.78–1.55) 1.10 (0.78–1.55)
  1. Values are expressed as n (%). aAdjusted for age (as a continuous variable), body mass index (<25 kg/m2, 25–29.99 kg/m2, >29.99 kg/m2), family history of breast cancer in first-degree relatives, menopausal status, family income (tertiles based on distribution of controls), lifetime months of breast feeding (never, 1–5, 6–15, ≥ 15 months) and study site. CI, confidence interval; OR, odds ratio.